Tetra Bio-Pharma Secures CBD Supply Agreement for Genacol Partnership
September 05 2018 - 8:00AM
Tetra Bio-Pharma Inc., a leader in
cannabinoid-based drug discovery and development (TSX VENTURE: TBP)
(OTCQB: TBPMF), is pleased to announce that it has secured a CBD
supply agreement with True North Cannabis in Alberta, Canada.
Tetra Bio-Pharma will develop a cannabinoid derived oral capsule
and a topical cream for treating joint pain and inflammation which
will be commercialized under the previously announced partnership
with Genacol.
Tetra Bio-Pharma will use its formulation and
regulatory expertise and clinical trial data from its topical
cannabinoid and encapsulated cannabis oil (PPP005) trials to create
these innovative products for Genacol. Tetra Bio-Pharma will
work with the appropriate regulatory agencies to gain marketing
authority within Genacol’s international sales network where their
brand products are available in more than 40 countries, including
Latin America, Europe, Asia, the Middle East, Africa and the United
States. In addition, the Genacol trademark is registered in 81
countries worldwide. According to industry statistics the market
for topical pain relief products exceeds $2.5 billion. The products
are expected to be launched in 2019.
“We are very pleased to secure a competitive
supply agreement with True North Cannabis as Tetra is committed on
bringing innovative cannabinoid products to market,” says Dr. Guy
Chamberland, interim CEO and Chief Scientific Officer of Tetra
Bio-Pharma. “True North Cannabis has built a state-of-the-art
facility in Alberta which will provide the highest quality CBD for
Tetra, at a competitive price, to develop innovative products in
partnership with Genacol. Price to consumers is a critical
aspect for the viability of a commercial product in the self-care
health market. At Tetra Bio-Pharma we are focused on becoming
a global leader in the development of cannabinoid derived
prescription and natural health products.”
“True North Cannabis is pleased to enter into a
commercial relationship to supply hemp-based CBD to Tetra
Bio-Pharma,” Shayne Hamilton, Chief Executive Officer of True North
Cannabis commented. “Our business leverages the size and
scale of the industrial hemp crop in Canada to provide a
competitively priced, reliable source of CBD. Tetra
Bio-Pharma’s vast experience in pharmaceutical product development,
along with Genacol’s robust distribution footprint, presents True
North Cannabis a unique opportunity to market our product.”
About Tetra
Bio-PharmaTetra Bio-Pharma (TSX-V: TBP) (OTCQB:
TBPMF) is a biopharmaceutical leader in cannabinoid-based drug
discovery and development with a Health Canada approved,
and FDA reviewed, clinical program aimed at bringing
novel prescription drugs and treatments to patients and their
healthcare providers. The Company has several subsidiaries engaged
in the development of an advanced and growing pipeline of Bio
Pharmaceuticals, Natural Health and Veterinary Products
containing cannabis and other medicinal plant-based elements. With
patients at the core of what we do, Tetra Bio-Pharma is
focused on providing rigorous scientific validation and safety data
required for inclusion into the existing bio pharma industry by
regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
About True North Cannabis
True North Cannabis (TNC) is a Canadian hemp harvest service
provider with a core focus on facilitating the supply of bulk,
extract-ready, hemp-based CBD.
With a grower-focused service model, TNC
supports industrial hemp growers across Canada to effectively
commercialize the cannabinoid content from their harvest. By
providing access to state of the art infrastructure and hemp chaff
expertise, TNC manages the unique challenges in bridging broad acre
agriculture and the Cannabis industry.
For more information visit: www.truenorthcannabis.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Forward-looking statementsSome
statements in this release may contain forward-looking information.
All statements, other than of historical fact, that address
activities, events or developments that the Company believes,
expects or anticipates will or may occur in the future (including,
without limitation, statements regarding potential acquisitions and
financings) are forward-looking statements. Forward-looking
statements are generally identifiable by use of the words "may",
"will", "should", "continue", "expect", "anticipate", "estimate",
"believe", "intend", "plan" or "project" or the negative of these
words or other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the inability of the
Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, including the ability to
obtain orphan drug status, the applicability of the discoveries
made therein, the successful and timely completion and
uncertainties related to the regulatory process, the timing of
clinical trials, the timing and outcomes of regulatory or
intellectual property decisions, and the success of its natural
health products development and commercialization strategies,
and other risks disclosed in the Company's public disclosure
record on file with the relevant securities regulatory authorities.
Although the Company has attempted to identify important factors
that could cause actual results or events to differ materially from
those described in forward-looking statements, there may be other
factors that cause results or events not to be as anticipated,
estimated or intended. Readers should not place undue reliance on
forward-looking statements. While no definitive documentation has
yet been signed by the parties and there is no certainty that such
documentation will be signed. The forward-looking statements
included in this news release are made as of the date of this news
release and the Company does not undertake an obligation to
publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by
applicable securities legislation.
For further information, please contact Tetra Bio-Pharma
Inc.Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514 Investors@tetrabiopharma.com
Media Contact energi PR Carol Levine
Carol.Levine@energipr.com 514-288-8500 ext. 225 416-425-9143 ext.
225
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From Apr 2024 to May 2024
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From May 2023 to May 2024